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Abstract
Background: The aim of the present study was to investigate the associations between endogenous testosterone
concentrations and the incidence of acute myocardial infarction (AMI) in men and women with and without type 2
diabetes.
Methods: The study comprised 1109 subjects ≥40 years of age (mean age 62 ± 12 years) participating in a baseline
survey in Sweden in 1993–94. Information about smoking habits and physical activity was obtained using validated
questionnaires. Serum concentrations of testosterone and sex hormone-binding globulin (SHBG) were obtained
using radioimmunoassay. Diagnosis of type 2 diabetes was based on WHO’s 1985 criteria. Individual patient
information on incident AMI was ascertained by record linkage with national inpatient and mortality registers from
baseline through 2011.
Results: The prevalence of type 2 diabetes at baseline was 10.0 % in men and 7.5 % in women. During a mean
follow-up of 14.1 years (±5.3), there were 74 events of AMI in men and 58 in women. In age-adjusted Cox models,
a significant inverse association between concentrations of testosterone and AMI-morbidity was found in men with
type 2 diabetes (HR = 0.86 CI (0.75–0.98)). In a final model also including waist-to-hip ratio, systolic blood pressure,
total cholesterol and active smoking, the association still remained statistically significant (HR = 0.754 CI (0.61–0.92)).
Conclusion: Low concentrations of testosterone predicted AMI in men with type 2 diabetes independent of other
risk factors. Trials with testosterone investigating the effect regarding cardiovascular outcome are still lacking. Future
trials in this field should take into account a modification effect of diabetes.
Background
Serum concentrations of testosterone in men decrease
with age [1]. Although the decrease may partially be at-
tenuated by increasing levels of sex hormone binding
globulin (SHBG) [2], obesity has a major independent
impact on the decrease in these levels [3]. On the other
hand, prospective studies have shown that low serum
levels of testosterone can independently predict both
obesity and diabetes [4]. This bidirectional relationship
between low testosterone and metabolic syndrome as
well as type 2 diabetes has been described in previous
studies [5]. The link between concentrations of serum
testosterone and type 2 diabetes has become a topic of de-
bate as two prospective studies have shown that SHBG
can also independently predict type 2 diabetes [6, 7].
Observational prospective studies and meta-analytical
studies have also shown that low concentrations of tes-
tosterone predict both all cause and cardiovascular mor-
tality in elderly populations [8–13]. There is an on-going
debate regarding mechanisms behind this association, as
it remains unclear whether concentrations of serum tes-
tosterone are a marker of aging in men, or whether tes-
tosterone per se influences the aging process and
atherosclerosis [14]. In fact, studies conducted in men
following an acute myocardial infarction (AMI) have
demonstrated that testosterone induces vasodilatation,
thus increasing coronary artery perfusion [15]. More-
over, accelerated atherosclerosis is observed in elderly
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castrated men [16]. However, epidemiological studies in-
vestigating the association between concentrations of
serum testosterone and AMI are still scarce. This ques-
tion may be especially important in individuals with type
2 diabetes who have accelerated atherosclerosis due to
impaired glucose metabolism. Concentrations of testos-
terone are low in this group; however, it is not known
whether low testosterone predicts greater risk of acute
myocardial infarction. A recent trial investigating the ef-
fects of testosterone replacement therapy (TRT) in pa-
tients with type 2 diabetes has shown beneficial effects on
insulin resistance (HOMA-ir) and on LDL-cholesterol
[17]. Moreover, a previous meta-analysis has shown that
TRT tends to improve glycaemic control and fat mass in
individuals with type 2 diabetes [18]. Nonetheless, there
is a lack of prospective studies investigating the associ-
ation between concentrations of testosterone and AMI-
morbidity in individuals with diabetes.
Apart from the general question of associations be-
tween concentrations of testosterone and cardiovascular
diseases, knowledge is limited with regard to this associ-
ation in women, and previous results are inconsistent
[19–21]. A recent prospective study showed a strong as-
sociation between free testosterone concentrations and
cardiovascular disease (CVD) mortality in postmeno-
pausal women with diabetes [22].
In light of these concerns, the present study aimed to
investigate the associations between endogenous testos-
terone concentrations and the incidence of acute myo-
cardial infarction in a population-based sample of men
and women with and without type 2 diabetes.
Research design and methods
Study population
In brief, this study is based on a population-based random
sample of men and women from Skara, a municipality in
south-western Sweden. The study was conducted in
1993–94 and 1109 subjects were included if they com-
pleted a standard physical examination, filled in the study
questionnaire, and provided venous blood for laboratory
assessment. The overall participation rate was 80 %. De-
tailed information about this population sample is pre-
sented elsewhere [23].
Medical history, socio-economic and life style factors
Standard questionnaires were used to collect informa-
tion on previous hospitalizations and chronic diseases,
and on smoking, alcohol habits, and leisure time phys-
ical activity (LTPA). Smoking was categorized as current,
former or daily smoking.
Physical examination
The physical examination included body height, weight,
and waist and hip circumference. Waist-to-Hip Ratio
(WHR) was calculated, as well as Body Mass Index
(BMI). Nurses measured blood pressures after a 5 min
rest by the study subjects, according to a standard proto-
col. Systolic and diastolic pressures were taken twice,
one minute apart, with the subject in a supine position,
at the right brachial artery and with the arm at heart
level, using a cuff size appropriate for arm circumference
and pressures recorded at the closest 2 mmHg [24].
Clinical chemistry
Samples including plasma and serum were drawn after
an overnight fast and were immediately frozen at − 82 °C.
Fasting blood glucose and an oral glucose tolerance test in
asymptomatic subjects with fasting blood glucose levels
≥6.7 mmol/L were the basis for diabetes mellitus diagnosis
according to the WHO criteria [25]. Clinical criteria in-
cluding age, body weight, symptoms at initial stage, ten-
dency to ketoacidosis, and treatment were used to define
type 1 and type 2 diabetes, respectively. Insulin resistance
was estimated using the homeostatic model assessment
for insulin resistance (HOMA-IR) [26]. Total cholesterol,
HDL-cholesterol, LDL-cholesterol and serum-triglycerides
were analysed using standard procedures.
Immunoassays were used to analyse concentrations of
sex hormones. Total testosterone was analysed at Skåne
University Hospital, Malmö, Sweden with Beckman
Coulter kit: 2003, 386982A (CV = 7–8 %). Sex hormone-
binding globulin (SHBG) (CV = 5 %) was analysed at
Unilabs at Skaraborg Hospital, Skövde, Sweden, using
Siemens Immulite kit 2000XPi [27]. Free testosterone
and estradiol were calculated using albumin levels mea-
sured in the same venous sample, and SHBG, according
to validated equations [28, 29]. The measurements of
SHBG and testosterone were unsuccessful in 4 of 1109
subjects; those 4 were excluded from the analyses.
Ethical considerations
All participants provided signed informed consent prior
to enrolment, and the Regional Ethical Review Board in
Gothenburg, Sweden, approved the study.
Outcomes
All participants were followed from the baseline examin-
ation until a first cardiovascular event or death, or other-
wise until December 31, 2011. All events were retrieved
by record linkage with the Swedish Cause of Death and
Hospital Discharge Registers, which is a valid alternative
to revised hospital discharge and death certificates [30, 31]
The outcomes considered in this study were non-fatal and
fatal events of AMI (ICD8 and 9: 410; ICD10: I21) [32].
Statistics
Analyses were performed using SPSS Statistics for Mac,
version 20. Normal distribution of testosterone was
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observed, while Homa-ir and s-insulin had skewed dis-
tributions, and logarithmic variables were used when
adjusting for these variables. Schoenfeld proportional
hazards were used to determine the feasibility of Cox re-
gression analysis. Cox Proportional Hazards Regression
was employed to investigate the associations between
levels of sex hormones at baseline and outcomes. Multi-
variate models were used to assess interactions and to
estimate the roles of possible confounders. Stratified
analyses for type 2 diabetes mellitus were computed to
investigate possible effect modification by diabetes. All
analyses were two-sided, and p < 0.05 was used as level
of statistical significance.
Results
The characteristics of the population at baseline are pre-
sented in Table 1. Men had significantly higher diastolic
blood pressure and Homa-ir than women, while the
prevalence of hypertension, type 2 diabetes, smoking,
and AMI was non-significantly higher than in women at
baseline. The differences in baseline characteristics be-
tween individuals with and without type 2 diabetes are
presented in Table 2. Subjects with type 2 diabetes had
higher systolic blood pressure, BMI, and WHR. At base-
line, men with type 2 diabetes had lower testosterone
concentrations than men without diabetes, but no differ-
ences in the levels of SHBG were observed. In both men
and women, the baseline prevalence of hypertension and
AMI was higher in participants with type 2 diabetes.
However, there were fewer smokers among subjects with
diabetes.
The mean follow-up time was 14.1 ± 5.3 years. During
that period, 74 AMI events occurred in men and 58 in
women in the total sample. The event rate was 10.3 per
1000 person years in men and 6.9 per 1000 person years
in women among participants without type 2 diabetes.
Among the total AMI events, 10 AMIs occurred in men
and 9 occurred in women, respectively, with diabetes.
The event rate was 13.8 per 1000 person years in men
with type 2 diabetes and 13.3 in women with type 2 dia-
betes. Kaplan-Meyer analyses for the highest quartile of
testosterone versus the three lower quartiles stratified by
gender were performed to investigate the association
with incident AMI. In men, the Kaplan-Meyer curves
were separated during the entire follow-up interval
(Fig. 1), and stratified analyses were then conducted for
men with and without type 2 diabetes. Among men with
diabetes, the rate of AMI was significantly lower in the
highest quartile of testosterone compared with the three
lowest quartiles. Although the tendency was similar in
men without diabetes, the findings in that group were
not statistically significant.
Table 3 shows the results from the Cox models of the
predictive effect of testosterone on AMI risk with adjust-
ments for important covariates. In the model including
all men regardless of diabetes status, the association be-
tween testosterone and AMI was marginally significant
in the age-adjusted analysis (HR = 0.950 95%CI 0.90–
1.00, p = 0.050). In the model adjusting for age, WHR,
smoking habits, physical activity, LDL and systolic blood
pressure, the association was not significant (HR = 0.949
95%CI 0.90–1.00 p = 0.069). An interaction term asses-
sing the relationship between testosterone and type 2
diabetes was marginally significant (p = 0.051). When
men with type 2 diabetes were analysed separately, a
strong association was found in the age-adjusted model,
which was further strengthened in the full model (HR =
0.754 95 % CI 0.61–0.92 p = 0.006). Models using free
testosterone showed similar results (Table 3).
In women, trends were similar with even lower
point estimates (suggesting protection) for the associ-
ations between testosterone and AMI; however, the
results were generally not statistically significant. One
model assessing the relationship between free testos-
terone and AMI in all women with full covariate ad-
justment was marginally significant (HR = 0.722. 95 %
CI 0.52–1.00, p = 0.046). Models testing the associa-
tions between SHBG and AMI showed no significant
associations.
Table 1 Characteristics of the population at baseline
Men Women
Mean SD Mean SD p
Age (y) 62.2 12.4 61.8 12.4 0.898
BMI (kg/m2) 26.4 3.29 26.5 4.66 0.700
WHR 0.93 0.06 0.81 0.07 <0.001
FB-glc (mmol/L) 5.1 1.4 4.9 1.1 0.046
Serum insulin (μUI/ml) 6.64 5.99 6.46 9.17 0.554
Homa-IR 1.5 1.5 1.3 1.2 0.045
Systolic blood pressure (mmHg) 137 21.0 139 22.7 0.448
Diastolic blood pressure (mmHg) 78 9.9 75 11 <0.001
Cholesterol (mmol/L) 5.9 1.4 6.1 1.7 0.532
Hormones
Testosterone (mmol/L) 13.5 4.36 1.00 0.62 <0.001
Free testosterone (mmol/L) 0.26 0.08 0.014 0.01 <0.001
SHBG (mmol/L) 39.2 16.5 54.4 26.1 <0.001
N % N %
Hypertension 126 22 117 22 0.899
Type 2 Diabetes Mellitus 51 9.8 40 7.3 0.063
Smoking 115 23 101 19 0.071
History of AMI 37 6.9 27 4.7 0.137
General linear models were used to estimate the difference between men and
women, respectively
SD standard deviation, BMI body mass index, FB-glc fasting blood glucose,
Homa-Ir homeostasis model of assessment - insulin resistance, BP blood
pressure, AMI acute myocardial infarction
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Discussion
In this study, a strong and independent association be-
tween concentrations of testosterone and AMI was ob-
served in men with type 2 diabetes. A trend was also
observed in the entire cohort regarding an inverse asso-
ciation between serum testosterone and AMI. The asso-
ciation in men was stronger than the association in
women, and it remained significant after adjustment for
age. The association was strongest among men with type
2 diabetes, where it remained significant with adjust-
ment for age and factors within the metabolic syndrome.
Previous studies in elderly men have shown an associ-
ation between low levels of testosterone and higher risk
for CVD [8, 10, 13]. While the evidence in elderly men
is very robust [11–13], prospective studies in younger
men are lacking. The cardiovascular impact of low tes-
tosterone in this group might be difficult to detect be-
cause of the low event rate. Another explanation might
be a modifying effect of age with regard to the testoster-
one effects in blood vessels. The levels of testosterone
might be more important in blood vessels where ageing
has occurred. This hypothesis is supported by our find-
ings. In fact, in the current data, the major impact of tes-
tosterone was observed among subjects with type 2
diabetes where early vascular ageing occurs [33]. However,
repeated measurements of testosterone concentration
would provide more information regarding the effects of
testosterone during ageing. Low testosterone concentra-
tions have previously been associated with the metabolic
syndrome [4]. There is evidence supporting an inverse re-
lationship between testosterone levels and the risk of de-
veloping type 2 diabetes and obesity [4].
However, the inverse relationship between testosterone
and incident AMI in men with type 2 diabetes remained
significant after the adjustment for age and metabolic
risk factors, suggesting other mechanisms to be involved.
One possibility is an effect on the coronary perfusion
through actions on the artery wall. Fukui et al. have re-
ported that low concentrations of endogenous androgens
were associated with increased artery stiffness in men
with type 2 diabetes [29, 34]. A similar result was re-
ported by Akishita et al. [35] in a study of the associ-
ation between endothelial function and testosterone
levels. Moreover, Web et al. [15] have shown a vaso-
active effect of testosterone in men with coronary dis-
ease, supporting the idea that testosterone might have
an independent vasoprotective effect. In contrast with
these findings, a recent observational study in the US
showed that hypogonadal men on testosterone replace-
ment therapy had a higher incidence of cardiovascular
events than controls [36]. However, the retrospective de-
sign of the study could not address possible selection
Table 2 Differences at baseline between subjects with and without T2D, respectively
Men Women
No diabetes Mean (SD) T2DM Mean (SD) p No diabetes Mean (SD) T2DM Mean (SD) p
Age y 62.2 (10) 70.5 (13) <0.001 61.9 (10) 73.2 (13) <0.001
BMI kg/m2 26.2 (3.2) 27.7 (4.4) 0.004 26.3 (4.5) 28.5 (5.1) 0.005
WHR 0.93 (0.1) 0.96 (0.1) 0.001 0.81 (0.1) 0.86 (0.1) <0.001
FB-glc mmol/L 4.8 (0.6) 7.9 (3.8) <0.001 4.8 (0.6) 7.7 (3.3) <0.001
S-insulin μUI/ml 6.2 (4.6) 8.8 (12.6) <0.001 5.7 (4.2) 9.2 (28.2) <0.001
Homa-Ir 1.3 (1.2) 3.1 (2.8) <0.001 1.2 (1) 3.2 (2.3) <0.001
SBP mmHg 136 (17) 150 (18) <0.001 138 (23) 152 (22) <0.001
DBP mmHg 78 (10) 81 (9) 0.076 75 (11) 76 (11) 0.445
Cholesterol mmol/L 6 (1.1) 5.9 (1.3) 0.702 6.1 (1.3) 6.1 (1.3) 0.896
Hormones
S-Testosterone mmol/L 13.7 (4.4) 11.7 (4.4) 0.002 1.0 (0.6) 1.2 (0.7) 0.047
S-SHBG mmol/L 39.7 (16) 40.2 (18) 0.845 54.9 (25) 47.7 (31) 0.077
Free testosterone mmol/L 0.26 (0.08) 0.21 (0.08) <0.001 0.01 (0.01) 0.02 (0.01) 0.001
N (%) N (%) N (%) N (%)
Hypertension 83 (17) 34 (63) <0.001 105 (20) 21 (49) <0.001
Smoking 113 (24) 5 (10) 0.021 101 (19) 2 (5) 0.017
History of AMI. 31 (6) 6 (11) 0.198 21 (4) 6 (14) 0.012
General linear models were used to estimate the difference between subjects with and without diabetes, respectively
T2DM type 2 diabetes, BMI body mass index, FB-glc fasting blood glucose, Homa-Ir homeostasis model of assessment - insulin resistance, SBP systolic blood
pressure, DBP diastolic blood pressure, AMI acute myocardial infarction
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bias, as individuals with a higher cardiovascular risk
might have been more likely to be treated with
testosterone.
The present study showed that in women, free testos-
terone had a greater impact on the risk of AMI than en-
dogenous testosterone. This may be an artefact of the
laboratory methods used, as the assays for testosterone
were developed to assess testosterone in men and opti-
mised for the male range, and thus less accurate in
women and children [37]. Furthermore, testosterone
production declines with the slowing of ovarian function
in menopause; however, this was not possible to take
into consideration here, as information about menopause
at baseline was lacking. It should also be mentioned that
this was a post-hoc analysis. Trials investigating the effects
of testosterone on the risk for cardiovascular disease are
lacking.
Another limitation of our study is the small number of
men with type 2 diabetes, as there is a risk of overesti-
mating effects in subgroup analyses [38]. However, the
consistency of these results across strata and the signifi-
cant findings despite the small sample size warrant
Fig. 1 Kaplan-Meyers curves show the differences in the survival between subjects in the highest quartile in green line and the other three
quartiles in red
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further investigation. The population-based sample and
high participation rate are major strengths of the study.
The long follow-up is also a strength, and the divergence
of the survival curves (Fig. 1) during the follow-up
period suggests a consistent relationship. Another
strength is the availability of a wide variety of risk factors
at baseline, which permitted adjustment for established
associations and assessment of possible confounding.
Conclusions
In conclusion, measuring testosterone in men with type
2 diabetes may help in the assessment of their cardiovas-
cular risk. Larger studies estimating the effects of low
testosterone levels in men with diabetes in relation to
AMI are needed. This study evaluated endogenous testos-
terone, and whether exogenous testosterone can reduce
AMI risk in men with diabetes and low concentrations of
testosterone also remains to be studied.
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